Medicare expands coverage for hereditary cancer genetic testing and preventive care

What it does

This bill expands Medicare coverage to include genetic testing for hereditary cancer mutations in people with a family history of cancer or personal risk factors, and covers preventive surgeries and enhanced cancer screenings for those found to carry high-risk mutations. The beneficiaries are Medicare patients at genetic risk of hereditary cancers; the mechanism is adding these services to Medicare's covered benefits without cost-sharing barriers.

Why we flagged it

The bill's operative mechanism is straightforward: it expands Medicare's covered benefits to include genetic testing and preventive services for hereditary cancer risk. This is a public health measure, not a regulatory change or industry carve-out.

What the text implies

• Genetic testing coverage may increase demand for counseling and follow-up services not explicitly mentioned in the bill; implementation costs depend on Medicare administrative contractor interpretation of 'evidence-based guidelines.'
• The bill defers to 'the least restrictive' guideline when oncology organizations conflict, potentially expanding coverage beyond current clinical consensus and increasing Medicare expenditure.
• Risk-reducing surgeries (e.g., prophylactic mastectomy, oophorectomy) are now covered as 'reasonable and necessary,' but the bill does not specify surgical eligibility criteria, leaving definition to administrative contractors and clinical guidelines.
• Annual screening frequency floor may conflict with some clinical guidelines that recommend more frequent screening for certain high-risk mutations, creating potential coverage disputes.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries with hereditary cancer risk gain access to genetic testing, preventive surgeries, and enhanced screenings that can detect cancer earlier or prevent it entirely, reducing mortality and morbidity. The bill imposes no new cost-sharing on patients and aligns coverage with evidence-based clinical guidelines, improving health outcomes for a vulnerable population.

Who stands to gain

• genetic testing laboratories and companies
• cancer screening providers (imaging centers, endoscopy facilities)
• surgical providers performing risk-reducing procedures
• oncology professional organizations (through guideline adoption authority)

Named in the bill

Medicare (Title XVIII, Social Security Act), National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), Society of Gynecologic Oncology (SGO), Medicare Administrative Contractors, Secretary of Health and Human Services

Where it stands

34 cosponsors: 26 Democrats, 8 Republicans.

• Jul 23, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 23, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $920,000 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Debbie Wasserman Schultz, the sponsor, reported $768,550 in PAC receipts in the 2026 cycle.

• Eisai Inc. — $790,000 on 1 filing
• The Susan G. Komen Breast Cancer Foundation, Inc. Dba Susan G. Komen — $130,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.